News & Updates
Filter by Specialty:
POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC
20 Jan 2023
byKanas Chan
Adding two immune checkpoint inhibitors, tremelimumab (T) and durvalumab (D), to platinum-based chemotherapy (CT) significantly improves overall survival (OS) and progression-free survival (PFS) vs CT alone in first-line treatment of metastatic non-small-cell lung cancer (mNSCLC), without causing a meaningful increase in toxicity, according to results of the phase III POSEIDON trial.
POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC
20 Jan 2023
Total diet replacement shows promise for difficult-to-treat asthma
19 Jan 2023
A low-calorie total diet replacement program (Counterweight-Plus) is safe and improves asthma control and quality of life in patients with difficult-to-treat asthma and obesity, according to 16-week data from a recent study.
Total diet replacement shows promise for difficult-to-treat asthma
19 Jan 2023
Behavioural therapy may improve physical activity, sleep quality in asthma patients
17 Jan 2023
Individuals with asthma may benefit from a behavioural intervention to increase their physical activity (PA), which may lead to improvements in quality of life and sleep, as well as a reduction in asthma and anxiety symptoms, suggest the results of a recent study.
Behavioural therapy may improve physical activity, sleep quality in asthma patients
17 Jan 2023
Regdanvimab for COVID-19 effective against Delta variant
13 Jan 2023
The neutralizing antibody regdanvimab appears to be useful in the treatment of mild-to-moderate COVID-19, with a recent study showing that the drug may prevent disease worsening in patients, including those infected with the Delta variant.